Head-to-head Intra-individual Comparison of Biodistribution and Tumor Uptake of [18F]FAPI-74 and [18F]FDG-PET/CT in Patients with PDAC

Ziel/Aim Pancreatic ductal carcinoma (PDAC) is epithelial cancer with prominent tumor stroma which, in line with>90% of other epithelial malignancies, exhibits a marked overexpression of fibroblast activation protein (FAP). Thus, Ga-labeled FAP ligands have provided very promising clinical results. However, due to well-known limitations regarding the use of Ga-labeling of radiopharmaceuticals, great efforts have been made to employ F-18 labeled FAP derivatives, i.e. [18F]FAPI-74. With this analysis of interim data from our ongoing prospective, proof-of-concept study, we sought to evaluate the biodistribution, tumor uptake, and lesion detectability in 5 patients with PDAC using [18F]FAPI-74 compared to [18F]FDG and contrast-enhanced CT, the current modality of choice for PDAC staging on an intraindividual basis.